Table 2.

Patient characteristics, immunosuppressive regimen, immunologic data, and details of vaccine administration

Patient no.	Age, yr	Sex	Ethnicity	Disease phenotype	ANCA type and titer at the time of second vaccine dose, U/ml	eGFR at the time of last RTX, ml/min per 1.73 m2	Proteinuria at the time of last RTX, mg	IS	Cumulative RTX dose, g	Vaccine type	Pre-RTX spike protein antibody titers, AU (negative, <1.24 AU)	Post-RTX spike protein antibody titers, AU (negative, <1.24 AU)	Duration elapsed between RTX and second antibody measurement, mo
1	57	Male	White	MPA	MPO (>100)	19	241	Induction: RTX + steroids; CYC + PLEX for refractory vasculitis (new diagnosis)	4	Pfizer–BioNTech	8.35	3.02	1
2	49	Female	White	MPA	MPO (>100)	39	1024	Induction: CYC + steroids Maintenance: RTX Relapse (3 mo after vaccine): RTX, CYC, and steroids	12	Pfizer–BioNTech	20	4.39	1
3	36	Male	White	GPA	PR3 (4.4)	96	190	Induction: CYC + steroids Maintenance: RTX	9	Pfizer–BioNTech	66	21.4	1
4	60	Male	White	GPA	MPO (<3.2)	50	130	Induction: RTX + steroids Maintenance: AZA transitioned to RTX	4.5	Pfizer–BioNTech	7.29	4.23	1

ANCA, anti–neutrophil cytoplasmic antibody; AU, arbitrary unit; AZA, azathioprine; CYC, cyclophosphamide; eGFR, estimated glomerular filtration rate; GPA, granulomatosis with polyangiitis; ID, identifier; IS, immunosuppression; MPA, microscopic polyangiitis; MPO, myeloperoxidase; PLEX, plasma exchange; PR3, proteinase 3; RTX, rituximab.